

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 399)

RESULTS OF THE RIGHTS ISSUE OF 3,649,352,418 RIGHTS SHARES ON THE BASIS OF THREE RIGHTS SHARES FOR EVERY TEN EXISTING SHARES HELD ON THE RECORD DATE

RESULTS OF THE RIGHTS ISSUE

As at 4:00 p.m. on Wednesday, 1 August 2012, being the latest time for acceptance of and payment for the Rights Shares, 9 valid acceptances of provisional allotments for a total of 2,599,669,825 Rights Shares (inclusive of 1,350,000,000 Rights Shares subscribed by the Undertaking Shareholder), representing approximately 71.24% of the total number of Rights Shares available for subscription under the Rights Issue, had been received.

The Underwriting Agreement and the Rights Issue became unconditional at 4:00 p.m. on Monday, 6 August 2012. Based on the above subscription results, the Rights Issue was under-subscribed by 1,049,682,593 Rights Shares, representing approximately 28.76% of the total number of Rights Shares available for subscription under the Rights Issue. Pursuant to the Underwriting Agreement, the Underwriter is required to take up or procure subscribers to take up 1,049,682,593 Rights Shares, being the difference between the total number of the Rights Shares of 3,649,352,418 available for subscription and the number of Rights Shares of 2,599,669,825 that have been subscribed by the Qualifying Shareholders.

As a result of the under-subscription of the Rights Shares by the Qualifying Shareholders, the Underwriter had procured a subscriber to subscribe for 1,049,682,593 Underwritten Shares, being the number of Rights Shares not taken up by the Qualifying Shareholders in the Rights Issue. As confirmed by the Underwriter, the independent subscriber will not become a substantial Shareholder upon completion of the Rights Issue. To the best of the Directors' knowledge, information and belief having made reasonable enquiries, the subscriber and their respective ultimate beneficial owners (if any) are Independent Third Parties.

DESPATCH OF SHARE CERTIFICATES FOR THE RIGHTS SHARES AND COMMENCEMENT OF DEALINGS OF THE RIGHTS SHARES IN FULLY-PAID FORM

It is expected that the share certificates for the Rights Shares, in their fully-paid form will be despatched by ordinary post to those entitled thereto, at their own risk, on Thursday, 9 August 2012. Dealings in the Rights Shares, in their fully-paid form, are expected to commence on the Stock Exchange at 9:00 a.m. on Friday, 10 August 2012.

Reference is made to the prospectus of United Gene High-Tech Group Limited (the “**Company**”) dated 18 July 2012 (the “**Prospectus**”) and the announcements of the Company dated 25 June 2012 and 11 July 2012 in respect of the Rights Issue. Capitalised terms used herein shall have the same meaning as those defined in the Prospectus unless otherwise stated.

RESULTS OF THE RIGHTS ISSUE

The Board is pleased to announce that as at 4:00 p.m. on Wednesday, 1 August 2012, being the latest time for acceptance of and payment for the Rights Shares, 9 valid acceptances of provisional allotments for a total of 2,599,669,825 Rights Shares (inclusive of 1,350,000,000 Rights Shares subscribed by the Undertaking Shareholder), representing approximately 71.24% of the total number of Rights Shares available for subscription under the Rights Issue, had been received.

The Underwriting Agreement and the Rights Issue became unconditional at 4:00 p.m. on Monday, 6 August 2012. Based on the above subscription results, the Rights Issue was under-subscribed by 1,049,682,593 Rights Shares, representing approximately 28.76% of the total number of Rights Shares available for subscription under the Rights Issue. Pursuant to the Underwriting Agreement, the Underwriter is required to take up or procure subscribers to take up 1,049,682,593 Rights Shares, being the difference between the total number of the Rights Shares of 3,649,352,418 available for subscription and the number of Rights Shares of 2,599,669,825 that have been subscribed by the Qualifying Shareholders.

As a result of the under-subscription of the Rights Shares by the Qualifying Shareholders, the Underwriter had procured a subscriber to subscribe for 1,049,682,593 Underwritten Shares, being the number of Rights Shares not taken up by the Qualifying Shareholders in the Rights Issue. As confirmed by the Underwriter, the independent subscriber will not become a substantial Shareholder upon completion of the Rights Issue. To the best of the Directors’ knowledge, information and belief having made reasonable enquiries, the subscriber and their respective ultimate beneficial owners (if any) are Independent Third Parties.

SHAREHOLDINGS IN THE COMPANY

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, the shareholding structure of the Company immediately before and after completion of the Rights Issue is as follows:

	Immediately before completion of the Rights Issue		Immediately after completion of the Rights Issue	
	No. of Shares	Approximate %	No. of Shares	Approximate %
Best Champion (<i>Note i</i>)	4,732,027,000	38.90	6,082,027,000	38.46
Public Shareholders:				
— Subscriber procured by the Underwriter	—	—	1,049,682,593	6.64
— Others	<u>7,432,481,062</u>	<u>61.10</u>	<u>8,682,150,887</u>	<u>54.90</u>
Total	<u>12,164,508,062</u>	<u>100.00</u>	<u>15,813,860,480</u>	<u>100.00</u>

Notes:

- (i) Best Champion, the Undertaking Shareholder, is the controlling shareholder of the Company. Best Champion is a non-wholly-owned subsidiary of United Gene Holdings, the entire issued share capital of which is wholly and beneficially owned by Dr. Mao. As such, immediately after the completion of the Rights Issue, Dr. Mao is deemed to be interested in 6,082,027,000 Shares held by Best Champion.

DESPATCH OF SHARE CERTIFICATES FOR THE RIGHTS SHARES AND COMMENCEMENT OF DEALINGS OF THE RIGHTS SHARES IN FULLY-PAID FORM

It is expected that share certificates for the Rights Shares, in their fully-paid form, will be despatched by ordinary post to those entitled thereto, at their own risk, on Thursday, 9 August 2012.

Dealings in the Rights Shares, in their fully-paid form, are expected to commence on the Stock Exchange at 9:00 a.m. on Friday, 10 August 2012.

On behalf of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 8 August 2012

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).